The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Biomarker (BM) evaluations in the phase III AVAglio study of bevacizumab (Bv) plus standard radiotherapy (RT) and temozolomide (T) for newly diagnosed glioblastoma (GBM).
Ryo Nishikawa
Consultant or Advisory Role - Roche
Frank Saran
Consultant or Advisory Role - Roche
Warren Mason
Consultant or Advisory Role - Roche
Wolfgang Wick
Consultant or Advisory Role - Lilly; Roche
Honoraria - MSD; Roche
Research Funding - Apogenix; Boehringer Ingelheim; MSD
Timothy Francis Cloughesy
Consultant or Advisory Role - Apogenics; Celgene; Genentech; Merck; Merck Serono; NewGen Therapeutics; Roche; Tocagen
Roger Henriksson
Consultant or Advisory Role - Roche
Honoraria - Roche
Magalie Hilton
Employment or Leadership Position - Roche
Josep Garcia
Employment or Leadership Position - Roche
Tobias Vogt
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Celine Pallaud
Employment or Leadership Position - Roche
Stock Ownership - Roche
Oliver L. Chinot
Consultant or Advisory Role - Roche
Honoraria - AstraZeneca; MSD; Roche
Research Funding - Merck; Roche